Cormorant Asset Management, LP Chemo Centryx, Inc. Transaction History

Cormorant Asset Management, LP

$1.43 Billion
Q3 2024

Shares

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2022 Aug 15, 2022	BUY	$15.36 - $27.51 $8.6 Million - $15.4 Million	560,000 Added 64.74%	1,425,000 $35.3 Million
Q1 2022 May 16, 2022	BUY	$22.22 - $39.12 $10.3 Million - $18.2 Million	465,000 Added 116.25%	865,000 $21.7 Million
Q4 2021 Feb 14, 2022	BUY	$18.38 - $40.5 $7.35 Million - $16.2 Million	400,000 New	400,000 $14.6 Million
Q2 2021 Aug 16, 2021	SELL	$9.59 - $50.88 $8.15 Million - $43.2 Million	-850,000 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$49.53 - $68.4 $17.3 Million - $23.9 Million	-350,000 Reduced 29.17%	850,000 $43.6 Million
Q4 2020 Feb 16, 2021	SELL	$47.25 - $65.16 $9.45 Million - $13 Million	-200,000 Reduced 14.29%	1,200,000 $74.3 Million
Q3 2020 Nov 16, 2020	SELL	$46.35 - $61.69 $13.9 Million - $18.5 Million	-300,000 Reduced 17.65%	1,400,000 $76.7 Million
Q2 2020 Aug 14, 2020	SELL	$38.58 - $65.07 $12.5 Million - $21.1 Million	-325,000 Reduced 16.05%	1,700,000 $97.8 Million
Q1 2020 May 15, 2020	SELL	$32.73 - $50.78 $28.6 Million - $44.4 Million	-875,000 Reduced 30.17%	2,025,000 $81.4 Million
Q4 2019 Feb 14, 2020	BUY	$6.81 - $39.55 $7.35 Million - $42.7 Million	1,080,000 Added 59.34%	2,900,000 $115 Million
Q3 2019 Nov 14, 2019	SELL	$6.47 - $8.96 $3.53 Million - $4.89 Million	-545,280 Reduced 23.05%	1,820,000 $12.3 Million
Q2 2019 Aug 14, 2019	SELL	$8.31 - $14.85 $1.33 Million - $2.39 Million	-160,620 Reduced 6.36%	2,365,280 $22 Million
Q1 2019 May 15, 2019	BUY	$10.01 - $13.89 $25.3 Million - $35.1 Million	2,525,900 New	2,525,900 $35.1 Million

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cormorant Asset Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Cormorant Asset Management, LP with notifications on news.